COUR’s breakthrough nanoparticle platform harnesses the immune system’s own learning power to induce tolerance to specific problematic antigens, while preserving all immune functionality.
Upon infusion, COUR nanoparticles bind to immune cells called monocytes. The particles surface is functionalized to enhance uptake, ensuring optimal targeted delivery.
These cells then travel to the spleen and liver, where they undergo apoptosis. There, the disease-specific antigens encapsulated within the particles are released.
The resulting debris is consumed by antigen presenting cells, which present the disease-specific antigens along with negative co-stimulating factors to the adaptive immune system. Adaptive immune T-cells interact with the antigen-presenting cells, and in the absence of inflammatory signals they “perceive” the antigen as self.
These T-cells respond by undergoing deletion or anergy… or by inducing a T regulatory response.
T regulatory cells then migrate to sites of disease, where they continually down regulate the immune response in the presence of the disease specific antigen.
By harnessing the immune system’s built-in learning and regulatory pathways, COUR nanoparticle technology can reprogram the immune system – providing clinicians with a breakthrough approach to treating autoimmune disease.
In Our Pipeline
We are rapidly advancing our pipeline of first-in-class therapies for immune-mediated diseases. Our novel nanoparticle platform is designed to induce disease-specific tolerance with the goal of treating treat many autoimmune and allergic diseases by changing the allergen encapsulated within the nanoparticle.
COUR’s team of researchers and scientist work together to harness cutting-edge science. We are engaged in multiple programs aiming to bring potential therapies to induce antigen-specific immune tolerance across many disease areas.